Shopping Cart 0
Cart Subtotal
USD 0

University of Massachusetts Medical School - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

University of Massachusetts Medical School (UMMS), a subsidiary of University of Massachusetts is a research and healthcare institute that offers educational services. The institute offers both under graduate and graduate programmes in various medical areas. It provides mental health and pediatric services. UMMS institute carries out both clinical and basic research in the areas of HIV, cancer, diabetes, infectious disease and molecular basis of disease. The institute offers its services through its various clinical partners. It provides health and science education through its graduate schools including the School of Medicine, Graduate School of Nursing and Graduate School of Biomedical Sciences. UMMS is headquartered in Worcester, Massachusetts, the US.

University of Massachusetts Medical School-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of Massachusetts Medical School, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Ophthotech Enters into Research Agreement with University of Massachusetts Medical School 11

Aevitas Therapeutics Enters into Research Agreement with University of Massachusetts Medical School 12

Wave Life Sciences Enters into Research Agreement with University of Massachusetts Medical School 13

Spark Therapeutics Enters into partnership with University of Massachusetts Medical School 14

AbCellera Biologics Partners with MassBiologics 15

Quad Technologies Partners with University of Massachusetts Medical School 16

Grifols Enters into Agreement with MassBiologics 17

Lysogene Enters into Agreement with University of Massachusetts Medical School and Auburn University 18

Voyager Therapeutics Enters into Agreement with MassBiologics 19

Licensing Agreements 20

Amarantus Bioscience Enters Into Licensing Agreement With University of Massachusetts Medical School 20

University of Massachusetts Medical School Enters Into Licensing Agreement With Agalimmune For Alphaject 21

University of Massachusetts Medical School-Key Competitors 22

University of Massachusetts Medical School-Key Employees 23

University of Massachusetts Medical School-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Strategy And Business Planning 25

May 10, 2018: Saint-Gobain Opens New Life Sciences Laboratory in Massachusetts 25

Oct 11, 2017: UMass Medical School announces The Li Weibo Institute for Rare Diseases Research 26

Government and Public Interest 28

Aug 13, 2018: New genome-editing strategy developed at UMMS may lead to therapeutics 28

Jul 18, 2018: John Harris lab identifies new pathway to reverse vitiligo 29

Jun 20, 2018: Riccio Fund for Neuroscience awards first research grants 30

Mar 21, 2018: Discovery of new ALS gene points to common role of cytoskeleton in disease 31

Mar 01, 2018: Prognostic role of elevated mir-24-3p in breast cancer 33

Dec 04, 2017: UMMS scientists identify gene associated with metastatic melanoma 34

Nov 14, 2017: St. Baldrick's Foundation Announces USD 2.2 Million in Grants to Give More Kids Access to Clinical Trials 35

Nov 03, 2017: Abraham Brass receives grant from Gilead for HIV research 36

Oct 19, 2017: New gene editing approach for alpha-1 antitrypsin deficiency shows promise in UMMS study 37

Oct 18, 2017: German Research Advances in Cancer and Blood Disorders Reported in Human Gene Therapy 38

Oct 17, 2017: UMMS researchers find possible correlation between retinal blood flow, obstructive sleep apnea 39

Oct 16, 2017: Gilead Awards USD 7.5 Million in Second Round of Grants to Advance HIV Cure Research 40

Oct 16, 2017: Postdoc Li-Chun Tu awarded NIH grant to study human chromosome dynamics 41

Jul 24, 2017: Craig Peterson receives USD 4.5 million outstanding investigator award from NIH 42

May 15, 2017: USD 2.6 Million in New Grants Spurs Innovation 43

Apr 25, 2017: UMMS researchers receive amfAR grant to eliminate HIV reservoirs using gene editing 46

Feb 27, 2017: Treatment Program for Children Experiencing Trauma Receives USD 2 Million Grant 47

Product News 48

Dec 22, 2017: WBUR: Promising treatment for diphtheria developed at UMMS needs funding to bring to trial 48

Jun 06, 2017: Data show five-year response for AAT deficiency gene therapy 49

Apr 23, 2018: New Mobile App Addresses Depression in Pregnant and Postpartum Women 50

Other Significant Developments 51

Aug 02, 2018: Muscle switch may control the benefits of exercise 51

Mar 15, 2018: Study Demonstrates Potential for SMRT Sequencing to Improve the Safety of Gene Therapy Protocols 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54


List Of Figure

List of Figures

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Key Facts 2

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of Massachusetts Medical School, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of Massachusetts Medical School, Deals By Therapy Area, 2012 to YTD 2018 9

University of Massachusetts Medical School, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Ophthotech Enters into Research Agreement with University of Massachusetts Medical School 11

Aevitas Therapeutics Enters into Research Agreement with University of Massachusetts Medical School 12

Wave Life Sciences Enters into Research Agreement with University of Massachusetts Medical School 13

Spark Therapeutics Enters into partnership with University of Massachusetts Medical School 14

AbCellera Biologics Partners with MassBiologics 15

Quad Technologies Partners with University of Massachusetts Medical School 16

Grifols Enters into Agreement with MassBiologics 17

Lysogene Enters into Agreement with University of Massachusetts Medical School and Auburn University 18

Voyager Therapeutics Enters into Agreement with MassBiologics 19

Amarantus Bioscience Enters Into Licensing Agreement With University of Massachusetts Medical School 20

University of Massachusetts Medical School Enters Into Licensing Agreement With Agalimmune For Alphaject 21

University of Massachusetts Medical School, Key Competitors 22

University of Massachusetts Medical School, Key Employees 23

University of Massachusetts Medical School, Subsidiaries 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

University of Massachusetts Medical School, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.